MedWatch

Hansa CEO prepares for launching the first product in 2020

Swedish biopharmaceutical company Hansa Biopharma has hired a new CFO few months after the company raised USD 50 million to finance the commercialization of the company's candidate against organ rejection in kidney transplantations.

Foto: Hansa Biopharma

In November last year, Swedish biopharmaceutical company Hansa Biopharma - former Hansa Medical - raised no less than USD 50 million in a directed share issue. Back then, CEO Søren Tulstrup said that the money was to "accelerate our commercial preparations for the potential launch of imlifidase", that is, the company's lead candidate to inhibit organ rejection after kidney transplantations.

About three months later, the company has taken one more step and appointed a new Chief Financial Officer (CFO) to ensure the financial basis for the launch of imlifidase, which is currently in phase II.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Selvtests til skoleelever er på lager – nyt udbud sat i gang

Der ligger antigentests klar på lager fra tidligere indkøb, og de dækker i første omgang behovet for selvtests til skoleelever, som Regeringen og KL forleden besluttede skal supplere de kommunale skolers testindsats. En nyt udbud er netop skudt i gang for at dække efterspørgslen, når lagrene er tømte, oplyser styrelse.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier